CRSP vs. IBRX, KRYS, IMVT, HALO, SWTX, EXEL, ACLX, IOVA, APGE, and DNLI
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include ImmunityBio (IBRX), Krystal Biotech (KRYS), Immunovant (IMVT), Halozyme Therapeutics (HALO), SpringWorks Therapeutics (SWTX), Exelixis (EXEL), Arcellx (ACLX), Iovance Biotherapeutics (IOVA), Apogee Therapeutics (APGE), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
ImmunityBio (NASDAQ:IBRX) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.
CRISPR Therapeutics has higher revenue and earnings than ImmunityBio. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 83.4% of ImmunityBio shares are held by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ImmunityBio currently has a consensus price target of $6.00, suggesting a potential downside of 9.37%. CRISPR Therapeutics has a consensus price target of $73.57, suggesting a potential upside of 34.16%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than ImmunityBio.
ImmunityBio has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.
In the previous week, CRISPR Therapeutics had 19 more articles in the media than ImmunityBio. MarketBeat recorded 21 mentions for CRISPR Therapeutics and 2 mentions for ImmunityBio. CRISPR Therapeutics' average media sentiment score of 1.25 beat ImmunityBio's score of 0.78 indicating that ImmunityBio is being referred to more favorably in the media.
CRISPR Therapeutics received 457 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 65.43% of users gave CRISPR Therapeutics an outperform vote while only 13.04% of users gave ImmunityBio an outperform vote.
CRISPR Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -198,994.05%. CRISPR Therapeutics' return on equity of 0.00% beat ImmunityBio's return on equity.
Summary
CRISPR Therapeutics beats ImmunityBio on 12 of the 18 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
Related Companies and Tools
